Global U.S. Influenza Vaccines Market Is Expanding Owing To Growing Government Initiatives to Support Influenza Vaccination And Increasing Vaccine Production Facilities

 

U.S. Influenza Vaccines Market

Overview:

Influenza vaccines are used to protect people at high risk for serious flu complications, including children, pregnant women and those with chronic health conditions. They help prevent the illness, reduce flu-related hospitalizations and save lives. Vaccines contain active flu viruses that have been modified or weakened. A single shot of an inactivated influenza vaccine (IIV) is generally effective for protecting against seasonal flu. Influenza vaccines can be given as an injection or as a nasal spray. They are also available as a trivalent or quadrivalent vaccine that contains 2 different types of flu viruses. The influenza vaccine is safe and has a good immune response in most healthy people. Some may experience mild side effects such as fever and sore throat. Symptoms usually clear up within a few days.

Market Dynamics:

Rising investments are estimated to augment growth of the global U.S. influenza vaccines market during the forecast period. For instance, USD 679 million were invested by Sanofi in a new vaccine manufacturing facility in Toronto in March 2021. This investment will help in boosting their supply chains in Europe and China.  Moreover, rising cost of R&D and the extended timeline for introducing a new vaccine are anticipated to restrain growth of the global U.S. influenza vaccines market during the forecast period.

Impact of COVID-19:

The pandemic was first reported in China and it led to shutting down the entire country. The COVID-19 virus affected the respiratory system and was being transmitted by coming in direct contact with an infected individual. To avoid any further transmission of the virus several nations imposed strict social distancing rules across the world. The pandemic resulted in increasing the demand for influenza vaccines, as the number of cases increased. There was no particular vaccine or drugs for treating COVID-19, so doctors were relying on such vaccines. This had a positive impact on the growth of the global U.S. influenza vaccines market.

Key Takeaways:

The global U.S. influenza vaccines market is estimated to witness robust growth, exhibiting CAGR of 16.3 % during the forecast period, due to rising research and developmental activities by key players. For instance, Vaxess Technologies Inc., declared the launch of a phase I trial for H1 influenza vaccine which will be delivered by Vaxess’s MIMIX patch, in August 2022.

North America is anticipated to witness robust growth in the global U.S. influenza vaccines market during the forecast period, due to rising product launches and increasing vaccine production facilities in the region.

Key players active in the global U.S. influenza vaccines market are EMERGEX VACCINES, GSK plc, OSIVAX, AstraZeneca, Viatris Inc., SINOVAC, Merck & Co., Inc., Pfizer Inc, EMERGENT, Vaxess Technologies Inc, and CSL Limited.